Generic Name and Formulations:
Fenoldopam mesylate 10mg/mL; soln for IV infusion after dilution; contains sodium metabisulfite.
Indications for CORLOPAM:
Adults: for the in-hospital, short-term (up to 48 hours) management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function. Children: for the in-hospital, short-term (up to 4 hours) reduction in blood pressure.
Give by continuous IV infusion. Doses from 0.01–1.6mcg/kg/min have been studied. Initial dose should be titrated upward or downward, no more frequently than every 15 minutes (and less frequently as goal pressure is approached) to achieve desired therapeutic effect. The recommended increments for titration are 0.05–0.1mcg/kg/min.
Give by continuous infusion pump appropriate for delivery of low infusion rates. Usual starting dose: 0.2mcg/kg/min; increased dosages of up to 0.3–0.5mcg/kg/min every 20–30 minutes were generally well tolerated.
Sulfite sensitivity. Glaucoma. Intraocular hypertension. Increased intracranial pressure. Acute cerebral infarction. Hemorrhage. Monitor BP, electrolytes. Pregnancy (Cat.B). Nursing mothers.
Avoid concomitant β-blockers.
Dopamine D1-like receptor agonist.
Headache, flushing, nausea, hypotension, tachycardia, hypokalemia.
Single-dose ampule (1mL, 2mL)—1
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine